Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Journal: The Lancet. Oncology
Published: June 22, 2022
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer.
Journal: mAbs
Published: November 01, 2021
Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
Journal: Cancer chemotherapy and pharmacology
Published: April 16, 2021
Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.
Journal: Cancer chemotherapy and pharmacology
Published: April 02, 2020
Transfusions and patient burden in chemotherapy-induced anaemia in France.
Journal: Therapeutic advances in medical oncology
Published: July 25, 2014
Physicians' preferences for bone metastases drug therapy in the United States.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 12, 2013
Progress in detecting cell-surface protein receptors: the erythropoietin receptor example.
Journal: Annals of hematology
Published: October 01, 2013
Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data.
Journal: Clinical epidemiology
Published: December 03, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026